01

HMNC Brain Health to Present on Advances in Precision Psychiatry and Psychedelics at CNS Summit 2024 in Boston

02

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024

03

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder ...

04

Ketabon To Present Advancements In At-Home Ketamine Therapy ...

05

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO® ...

06

Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression

07

Ray of Hope

A New, Take-At-Home Ketamine Pill is a Gamechanger for Treatment-Resistant Depression

08

HMNC Brain Health to participate in the psychedelic science conference 2023 and the H.C. Wainwright & Co. 4th annual Neuropsychiatry conference

09

HMNC Brain Health begins Phase 2 Study for personalized treatment of Stress-Axis related Major depressive Disorder (MDD)

10

How AI is Enhancing Precision Medicine for Psychiatry

Clinical Precision: Why Gene-Reading AI has Huge Potential for Psychiatric Treatment

11

HMNC BRAIN HEALTH APPOINTS EVAN PAPANASTASIOU AS VP CLINICAL DEVELOPMENT

Pharmaceutical Physician, Clinical Neuroscientist, and Psychiatrist with professional experience in the pharmaceutical industry accelerates Company efforts in clinical development

12

HMNC BRAIN HEALTH AND DEVELCO PHARMA ANNOUNCE LAST PATIENT BEING RANDOMIZED IN ORAL PROLONGED-RELEASE KETAMINE (KET01) TRIAL FOR TREATMENT-RESISTANT DEPRESSION

13

HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies

Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer

14

Maximilian Doebler Appointed Chief Business Officer of HMNC Brain Health

In his new role, Dr. Doebler will be responsible for all business and corporate development activities at the Company and will assume full responsibility for partnership agreements.

15

First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)

16

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD) ...

17

HMNC Brain Health Appoints Dr. Bertram Müller-Myhsok as Head of Precision Psychiatry

Appointment accelerates Company’s development roadmap in targeted therapies for neuropsychiatric disorders

18

HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder

In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects

19

Personalised Medicine for Psychiatry Requires Novel Trial Designs

An inspiring article in the latest Issue of International Clinical Trials: Our Chief Clinical Development Officer, Dr. Hans Eriksson shares his expertise about the requirements of novel trial designs in personalized medicine for psychiatry.

20

HMNC BRAIN HEALTH Appoints Head of Regulatory Affairs

Dr. Katarina Jelic Maiboe brings significant global regulatory affairs experience to the executive management team

21

HMNC Brain Health to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th

HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies ...

22

HMNC BRAIN HEALTH INITIATES PIONEERING PRECISION THERAPY PROGRAM IN MENTAL HEALTH

Pioneering the first large-scale double-blind studies to test the combination of therapies and genetic companion diagnostics in the area of mental health ...

23

HMNC BRAIN HEALTH TO PRESENT AT THE H.C. WAINWRIGHT 23RD ANNUAL GLOBAL INVESTMENT CONFERENCE

Munich, September 7, 2021 – HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering ...

24

HMNC BRAIN HEALTH AND DEVELCO PHARMA PARTNER TO INITIATE KETAMINE STUDY TARGETING TREATMENT-RESISTANT DEPRESSION (TRD)

Phase II Proof-of-Concept to study TRD patients ...

25

HMNC BRAIN HEALTH RAISES EUR 9 MILLION

Total Funds Raised to Date of EUR 28 Million From Prominent Investors Positions Company for Series B Round in 2021.

26

HMNC BRAIN HEALTH EMBARKS ON NEXT PHASE OF GROWTH WITH NEW LEADERSHIP TEAM

Munich, April 22, 2021. HMNC Brain Health, a biotech company focused on the development of innovative ...

27

HMNC APPOINTS NEW CHIEF CLINICAL DEVELOPMENT OFFICER

February 1, 2021 HMNC Holding GmbH, a biopharma company focused on the development of innovative and personalized treatments for depression and anxiety disorders ...

28

PROF. FLORIAN HOLSBOER IS ONE OF THE MOST QUOTED SCIENTISTS WORLDWIDE

Of 7 million researchers, he ranks among the top 500 in the ranking of Stanford University and Public Library of Science (PLOS).

29

CLINICAL TRIAL FOR PERSONALIZED THERAPY OF DEPRESSION STARTED

Florian Holsboer wants to help patients faster and more specifically with a personalized treatment approach

30

HMNC EXPANDS MANAGEMENT BOARD

Rainer Sturm (49) is the new CFO of HMNC Holding. Mr. Sturm has over 25 years of experience in financial management of corporate and start-up companies

31

FLORIAN HOLSBOER IN CONVERSATION WITH LIFE SCIENCES MAGAZINE

transkript spoke with Florian Holsboer, Managing Director of HMNC Holding GmbH, about the world‘s first stratification test for antidepressants and the company‘s own pipeline